NCT04878835View on ClinicalTrials.gov

Effects of Ranibizumab in Primary Pterygium Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

April 1, 2020

Study Completion Date

April 30, 2020

Conditions
Patients With Primary Nasal Pterygium
Interventions
BIOLOGICAL

intralesional ranibizumab

Lucentis; Genentech, Inc, San Francisco, California, USA 0.5mg/ 0.05mL

Trial Locations (1)

16150

Hospital Universiti Sains Malaysia, Kota Bharu

All Listed Sponsors
lead

Universiti Sains Malaysia

OTHER

NCT04878835 - Effects of Ranibizumab in Primary Pterygium Surgery | Biotech Hunter | Biotech Hunter